Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Significant Drop in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 21,126 shares, a decrease of 67.6% from the January 29th total of 65,207 shares. Based on an average daily trading volume, of 155,980 shares, the short-interest ratio is presently 0.1 days. Approximately 0.9% of the shares of the company are sold short. Approximately 0.9% of the shares of the company are sold short. Based on an average daily trading volume, of 155,980 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

VRAX has been the topic of a number of recent research reports. Zacks Research raised Virax Biolabs Group to a “hold” rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Friday, January 9th. Finally, HC Wainwright restated a “buy” rating and set a $1.00 price objective (down from $3.00) on shares of Virax Biolabs Group in a research report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Virax Biolabs Group currently has an average rating of “Hold” and a consensus target price of $1.00.

Virax Biolabs Group Price Performance

Virax Biolabs Group stock opened at $0.23 on Friday. Virax Biolabs Group has a one year low of $0.20 and a one year high of $1.84. The business has a fifty day moving average of $0.29 and a two-hundred day moving average of $0.47.

Virax Biolabs Group (NASDAQ:VRAX) last announced its quarterly earnings results on Tuesday, December 2nd. The company reported ($0.27) earnings per share (EPS) for the quarter. The firm had revenue of $0.00 million for the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.